510 lines
91 KiB
Text
510 lines
91 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK609658">
|
|
<meta name="ncbi_domain" content="niceng23er3">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK609658/?report=reader">
|
|
<meta name="ncbi_pagename" content="Managing genitourinary symptoms – breast cancer recurrence - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Managing genitourinary symptoms – breast cancer recurrence - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Managing genitourinary symptoms – breast cancer recurrence">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2024/11">
|
|
<meta name="citation_pmid" content="39631005">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK609658/">
|
|
<meta name="citation_keywords" content="Menopause">
|
|
<meta name="citation_keywords" content="Female Urogenital Diseases">
|
|
<meta name="citation_keywords" content="Urogenital System">
|
|
<meta name="citation_keywords" content="Breast Neoplasms">
|
|
<meta name="citation_keywords" content="Climacteric">
|
|
<meta name="citation_keywords" content="Perimenopause">
|
|
<meta name="citation_keywords" content="Risk Factors">
|
|
<meta name="citation_keywords" content="Recurrence">
|
|
<meta name="citation_keywords" content="Estrogens">
|
|
<meta name="citation_keywords" content="Ospemifene">
|
|
<meta name="citation_keywords" content="Dehydroepiandrosterone">
|
|
<meta name="citation_keywords" content="Laser Therapy">
|
|
<meta name="citation_keywords" content="Vaginal Creams, Foams, and Jellies">
|
|
<meta name="citation_keywords" content="Female">
|
|
<meta name="citation_keywords" content="Humans">
|
|
<meta name="citation_keywords" content="Review">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Managing genitourinary symptoms – breast cancer recurrence">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2024/11">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK609658/">
|
|
<meta name="og:title" content="Managing genitourinary symptoms – breast cancer recurrence">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK609658/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng23er3-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng23er3/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK609658/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8EEE937D6B972100000000001D0017.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK609658/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK609658/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK609658/&text=Managing%20genitourinary%20symptoms%20%02013%20breast%20cancer%20recurrence"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK609658/?report=classic">Switch to classic view</a><a href="/books/n/niceng23er3/pdf/">PDF (1.0M)</a><a href="/books/n/niceng23er3/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK609658%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8EEE937D6B972100000000001D0017.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng23er3-lrg.png" alt="Cover of Managing genitourinary symptoms – breast cancer recurrence" /></a></div><div class="bkr_bib"><h1 id="_NBK609658_"><span itemprop="name">Managing genitourinary symptoms – breast cancer recurrence</span></h1><div class="subtitle">Menopause (update)</div><p><b>Evidence review B2</b></p><p><i>NICE Guideline, No. 23</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2024 Nov</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-6560-1</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2024.</div></div><div class="bkr_clear"></div></div><div id="niceng23er3.s1"><h2 id="_niceng23er3_s1_">Managing genitourinary symptoms – breast cancer recurrence</h2><div id="niceng23er3.s1.1"><h3>Review question</h3><p>Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</p><div id="niceng23er3.s1.1.1"><h4>Introduction</h4><p>Genitourinary symptoms associated with menopause can be severe and debilitating, normally treated by localised vaginal oestrogens. For women with a personal history of breast cancer (including those on no adjuvant therapy, tamoxifen or aromatase inhibitors) a difficult decision has to be made due to uncertainty over whether localised vaginal oestrogens can increase the risk of breast cancer recurrence, leaving women with potentially less effective options for treatment.</p></div><div id="niceng23er3.s1.1.2"><h4>Summary of the protocol</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng23er3tab1"><a href="/books/NBK609658/table/niceng23er3.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img" rid-ob="figobniceng23er3tab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng23er3.tab1"><a href="/books/NBK609658/table/niceng23er3.tab1/?report=objectonly" target="object" rid-ob="figobniceng23er3tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">Summary of the protocol (PICO table). </p></div></div><p>For further details see the review protocol in <a href="#niceng23er3.appa">Appendix A</a>.</p></div><div id="niceng23er3.s1.1.3"><h4>Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng23er3.appa">Appendix A</a> and the <a href="/books/NBK609658/bin/NG23-Menopause-supplement-1-methods.pdf">methods</a> document (Supplement 1).</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p></div><div id="niceng23er3.s1.1.4"><h4>Effectiveness evidence</h4><div id="niceng23er3.s1.1.4.1"><h5>Included studies</h5><p>Overall, 4 studies were included in this review, 1 prospective cohort study (<a class="bibr" href="#niceng23er3.s1.1.ref1" rid="niceng23er3.s1.1.ref1">Cold 2022</a>) and 3 retrospective cohort studies (<a class="bibr" href="#niceng23er3.s1.1.ref2" rid="niceng23er3.s1.1.ref2">Dew 2003</a>, <a class="bibr" href="#niceng23er3.s1.1.ref3" rid="niceng23er3.s1.1.ref3">Le Ray 2012</a> and <a class="bibr" href="#niceng23er3.s1.1.ref4" rid="niceng23er3.s1.1.ref4">O’Meara 2001</a>).</p><p>All studies included women with a history of breast cancer and compared the use of vaginal oestrogens to no treatment.</p><p>The included studies are summarised in <a href="/books/NBK609658/table/niceng23er3.tab2/?report=objectonly" target="object" rid-ob="figobniceng23er3tab2">Table 2</a>.</p><p>See the literature search strategy in <a href="#niceng23er3.appb">Appendix B</a> and study selection flow chart in <a href="#niceng23er3.appc">Appendix C</a>.</p></div><div id="niceng23er3.s1.1.4.2"><h5>Excluded studies</h5><p>Studies not included in this review are listed, and reasons for their exclusion are provided in <a href="#niceng23er3.appj">Appendix J</a>.</p></div></div><div id="niceng23er3.s1.1.5"><h4>Summary of included studies</h4><p>Summaries of the studies that were included in this review are presented in <a href="/books/NBK609658/table/niceng23er3.tab2/?report=objectonly" target="object" rid-ob="figobniceng23er3tab2">Table 2</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng23er3tab2"><a href="/books/NBK609658/table/niceng23er3.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img" rid-ob="figobniceng23er3tab2"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng23er3.tab2"><a href="/books/NBK609658/table/niceng23er3.tab2/?report=objectonly" target="object" rid-ob="figobniceng23er3tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of included studies. </p></div></div><p>See the full evidence tables in <a href="#niceng23er3.appd">Appendix D</a> and the forest plots in <a href="#niceng23er3.appe">Appendix E</a>.</p></div><div id="niceng23er3.s1.1.6"><h4>Summary of the evidence</h4><p>For this review outcomes have been judged for clinical importance based on statistical significance. Please see <a href="/books/NBK609658/bin/NG23-Menopause-supplement-1-methods.pdf">Supplement 1</a> for further details.</p><div id="niceng23er3.s1.1.6.1"><h5>Vaginal oestrogen versus no treatment</h5><p>Very low-quality evidence showed no important difference for breast cancer recurrence between vaginal oestrogen and no treatment in a population of women with a history of breast cancer, that used adjuvant treatment and those that did not. There was no evidence in people at high risk of developing breast cancer, for example due to genetic risk, but no previous history of breast cancer.</p><p>Very low-quality evidence, in a population of women not using adjuvant treatment for breast cancer, showed no important difference in the risk of breast cancer recurrence for those who used local vaginal oestrogens, and those that did not.</p><p>Low quality evidence showed no important difference in the risk of recurrence in women using local vaginal oestrogens if they were using tamoxifen therapy for breast cancer, compared to those that did not use local vaginal oestrogens. Low quality evidence from one study showed that for women taking aromatase inhibitors or aromatase inhibitors in sequence with tamoxifen, the use of local vaginal oestrogens increased the risk of breast cancer recurrence. However, there was very low-quality evidence showing no difference from a separate study between use of local vaginal oestrogens or not, in those women that used either tamoxifen or aromatase inhibitors for breast cancer.</p><p>All of the evidence was downgraded for risk of bias, mainly due to not enough information available on adherence to treatment, and some issues around controlling for confounders. There were also concerns around imprecision.</p><p>There was no evidence for the outcomes incidence of ovarian cancer, or incidence of endometrial cancer.</p><p>See <a href="#niceng23er3.appf">Appendix F</a> for full GRADE tables.</p></div></div><div id="niceng23er3.s1.1.7"><h4>Economic evidence</h4><div id="niceng23er3.s1.1.7.1"><h5>Included studies</h5><p>A systematic review of the economic literature was conducted but no economic studies were identified which were applicable to this review question.</p><p>A single economic search was undertaken for all topics included in the scope of this guideline. See <a href="/books/NBK609658/bin/NG23-Menopause-supplement-2-health-economics.pdf">Supplement 2</a> for details.</p></div><div id="niceng23er3.s1.1.7.2"><h5>Excluded studies</h5><p>Economic studies not included in this review are listed, and reasons for their exclusion are provided in <a href="#niceng23er3.appj">Appendix J</a>.</p></div></div><div id="niceng23er3.s1.1.8"><h4>Summary of included economic evidence</h4><p>No economic studies were identified which were applicable to this review question.</p><p>One UK economic evaluation was identified for evidence review B1 (<a class="bibr" href="#niceng23er3.s1.1.ref5" rid="niceng23er3.s1.1.ref5">Dymond 2021</a>). This study compared ospemifene plus lubricant or moisturiser to lubricant or moisturiser alone to treat genitourinary symptoms associated with the menopause transition in women contraindicated for local oestrogen treatment. This contraindication included those for which local oestrogen treatment was not medically appropriate (including those with a history of breast cancer), was inconvenient or had previously been ineffective including because of adverse events. Although the population of the study did not match that required for inclusion in this evidence review this study was considered by the committee in forming recommendations.</p><p>The study took a UK NHS perspective and reported outcomes in terms of cost per QALY. It found ospemifene plus moisturiser/lubricant to be cost effective at a £20,000 per QALY threshold compared to moisturiser/lubricant alone. This conclusion was robust to alternative assumptions. The study was directly applicable with minor methodological limitations in respect to review question B1. Given the population of the study it is only partially applicable to this review question.</p><p><a class="bibr" href="#niceng23er3.s1.1.ref5" rid="niceng23er3.s1.1.ref5">Dymond 2021</a> is summarised in full in evidence review B1.</p></div><div id="niceng23er3.s1.1.9"><h4>Economic model</h4><p>No economic modelling was undertaken for this review. An economic model of treatments for genitourinary symptoms associated with the menopause transition, which did not exclude the population considered by this review, was developed for evidence review B1. This model was used to influence recommendations made for this review. The model is reported in full in evidence review B1. Whilst the population for the economic model include this population group it is not exclusive to it and results from the model are therefore only partially applicable to this review question.</p></div><div id="niceng23er3.s1.1.10"><h4>The committee’s discussion and interpretation of the evidence</h4><div id="niceng23er3.s1.1.10.1"><h5>The outcomes that matter most</h5><p>The committee chose the outcome incidence or recurrence of breast cancer as the critical outcome for this review. The committee agreed that women who experience genitourinary symptoms such as vaginal dryness with a history of breast cancer are faced with a difficult choice as to whether it is safe for them to use local vaginal oestrogens. Vaginal oestrogen is absorbed into the blood stream, but to a lesser degree than systemic oestrogen. Systemic HRT is contraindicated because of absorption of oestrogen, and therefore the impact of vaginal oestrogen on breast cancer recurrence was considered particularly important.</p><p>The committee chose incidence of ovarian cancer and incidence of endometrial cancer as important outcomes for this review. The committee agreed that women with a history of breast cancer, or at an increased risk of developing breast cancer, may also have an increased risk of developing ovarian and endometrial cancer. They therefore wanted to consider the safety of using local vaginal oestrogens on the risk of developing these cancers, too.</p></div><div id="niceng23er3.s1.1.10.2"><h5>The quality of the evidence</h5><p>The quality of the evidence was assessed with GRADE and ranged from very low to low quality. All the evidence was downgraded for risk of bias. This was due to the studies not adjusting for all the appropriate confounders, such as BMI and age at menopause. There were also concerns around deviations from the intended intervention not being investigated or taken into consideration, as successful intervention implementation was based on the assumption that all those who received a prescription for local vaginal oestrogens did go on to use the treatment. The evidence was also downgraded for concerns around imprecision.</p><p>There was a lack of evidence on ospemifene, prasterone and transvaginal laser therapy, and no evidence was identified for the outcomes: incidence of ovarian cancer or incidence of endometrial cancer.</p></div><div id="niceng23er3.s1.1.10.3"><h5>Benefits and harms</h5><p>The committee discussed the evidence on local vaginal oestrogens and the risk of breast cancer recurrence and agreed that the limitations of the evidence would need to be carefully considered when making recommendations. The committee discussed that some of the evidence had been downgraded in quality due to a lack of adjustment for important confounders regarding the prognostic variables of breast cancer, which would have an impact on the risk of recurrence. There were some uncertainties around the effect size of outcomes with wide confidence intervals making results potentially consistent with no difference, a small increase or a small decrease in breast cancer recurrence. The committee also discussed the possibility of potential bias by indication, where clinicians may prescribe local vaginal oestrogens to people who were at a lower risk of breast cancer recurrence. Given these factors, along with the relatively short length of follow-up in some studies, the committee agreed to be cautious when making recommendations.</p><p>The committee discussed the evidence comparing vaginal oestrogen to no treatment in women with a history of breast cancer. Most of the evidence showed no difference in breast cancer recurrence between women who used and did not use local vaginal oestrogens on breast cancer recurrence. There was evidence that was stratified according to whether people had used adjuvant treatment or not, and this showed no difference in breast cancer recurrence between users and non-users of local vaginal oestrogens in a population of those not using adjuvant treatment. The committee discussed the concerns around imprecision for this evidence and the wide confidence intervals around the effect estimates. The committee also discussed some of the evidence on a combined population of women who had and had not used adjuvant treatment for breast cancer, that showed no difference in risk of recurrence when using local vaginal oestrogens. The committee discussed their concerns regarding the small sample sizes of the two studies that were driving this effect, which contributed to the uncertainty in the size of this effect. There were also concerns around insufficient information in relation to any adjuvant treatment from the study characteristics related to the groups of people receiving the intervention and comparison treatment. The committee agreed that the quality of the evidence meant they could not be confident around the safety of local vaginal oestrogens. They agreed on the importance of a discussion between the clinician and the person on all available treatments. The committee agreed that they would make a recommendation that people should be given non-hormonal local options as a first line treatment of genitourinary symptoms, as the uncertainty around local vaginal oestrogen safety (in terms of effect size and evidence quality) may mean that this would be the option with the least risk.</p><p>The committee felt the evidence for local vaginal oestrogens was inconclusive in giving a clear direction of effect, therefore they decided that local vaginal oestrogens should be considered only when non-hormonal options have been ineffective, and the person is still troubled by the genitourinary symptoms. The committee were mindful that whilst there may be a small uncertain impact of local vaginal oestrogen on increased or decreased risk of breast cancer recurrence, it would need to be balanced against any reduction in quality of life due to the symptoms experienced. The committee noted that people may not realise that non-hormonal moisturisers and lubricants could also be used in combination with vaginal oestrogen, so they agreed to highlight this.</p><p>The committee discussed the evidence related to use of local vaginal oestrogens in those taking adjuvant treatment for breast cancer, specifically tamoxifen and aromatase inhibitors. The committee discussed the evidence for tamoxifen, which showed a possible reduction in the risk of breast cancer recurrence with local vaginal oestrogen use compared with no use, however this did not reach statistical significance. The committee acknowledged that this was unlikely to be a true effect of the local vaginal oestrogens, and more likely a result of adherence to treatment. They discussed that tamoxifen use is associated with fewer genitourinary symptoms due to the mechanism of action, compared with aromatase inhibitors and therefore may lead to a decreased adherence to vaginal oestrogen and increased adherence to tamoxifen treatment.</p><p>The committee went on to discuss the evidence around the risk of breast cancer recurrence with vaginal oestrogen in people who also use aromatase inhibitors as an adjunct treatment for their breast cancer. The committee discussed that the evidence available was for a combination of aromatase inhibitors used as an adjunct to breast cancer treatment either alone, or in sequence with tamoxifen. They acknowledged that there was no evidence for aromatase inhibitor use alone. The committee agreed that the mechanism of action of aromatase inhibitors which makes genitourinary symptoms more likely, could describe why the evidence suggested an increased risk of breast cancer recurrence seen in this combined (aromatase inhibitor and/or tamoxifen) group, and not in the tamoxifen only group which has a mechanism of action which makes genitourinary symptoms less likely. It is possible that this may have led to lower adherence related to the adjuvant aromatase inhibitor treatment which was then impacting on breast cancer recurrence rather than necessarily being a direct effect of vaginal oestrogen. However, they discussed that the number of women was much smaller in this group, and also noted the overall low quality of the evidence, and therefore agreed they could not reach a conclusion regarding the effect of local vaginal oestrogens on breast cancer recurrence risk in those using aromatase inhibitors.</p><p>The committee agreed that overall, they could not be confident in the evidence with regard to the safety of local vaginal oestrogens in those taking either tamoxifen or aromatase inhibitors as adjuvant therapy for breast cancer, due to the concerns around the quality of the evidence, and lack of data on aromatase inhibitor use only. However, using their expertise the committee agreed that when vaginal oestrogen is considered for people on aromatase inhibitors, advice from an oncology specialist should be sought about treatment options which could include switching from adjuvant treatment with aromatase inhibitors to tamoxifen may be an option for those who want to use local vaginal oestrogens. .</p><p>The committee discussed, based on experience, that treatment decisions including considerations related to safety of vaginal oestrogen would need to be tailored to each person. Some people have a lower risk of breast cancer recurrence than others (as covered by <a href="https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#endocrine-therapy" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s guideline on early and locally advanced breast cancer</a>). The committee decided that this was an important factor because it is worse to potentially add to the risk of those who already have a high risk than those who have a low risk of recurrence. They also noted that vaginal oestrogen is absorbed locally. Some of it is absorbed systemically, that is, further into the body, but, compared to systemic HRT, the amount is minimal, and so it may or may not be an amount that would affect breast cancer recurrence. This makes it difficult to assess the safety of vaginal oestrogen with respect to breast cancer recurrence.</p><p>In someone with an oestrogen-receptor negative breast cancer, oestrogen does not affect the growth of cancer cells, but in someone with an oestrogen-receptor positive breast cancer, it boosts it. The committee discussed that in someone with an oestrogen-receptor positive breast cancer taking adjuvant treatment if this treatment inhibits the production of oestrogen (in the ovaries or in fat or muscle tissues), it will have no effect on any oestrogen coming from a source outside the body, and this oestrogen would then be able to bind to cancer cells and stimulate their growth but if this treatment stops oestrogen from binding to oestrogen receptors (regardless of whether the oestrogen is produced by the body or absorbed from some treatment), it will stop oestrogen, regardless of source, from binding to receptors on cancer cells and so their growth will not be stimulated.</p><p>The committee acknowledged that the population in the evidence referred to people with a history of breast cancer rather than people at a high risk of breast cancer by being a carrier of a genetic variant associated with a higher breast cancer risk (such as <i>BRCA1/2</i>). They therefore could not comment on populations with a high inherited risk of breast cancer but noted that this population would be included in the analysis review question on the effectiveness of treatments for genitourinary symptoms and would be reported as a subgroup if relevant data were identified.</p><p>The committee agreed that the uncertainty within the evidence (and the relatively small amount of identified evidence) of the effects of vaginal oestrogen on breast cancer recurrence warranted a research recommendation which was formulated to address the gaps in the evidence (for details see <a href="#niceng23er3.appk">Appendix K</a>).</p></div><div id="niceng23er3.s1.1.10.4"><h5>Cost effectiveness and resource use</h5><p>The recommendations for this topic mirror current practice. There may be a small increase in the use of local oestrogens if women with a history of breast cancer decide on this treatment after non-hormonal approaches have been ineffective and possible risks discussed and considered. This would lead to an increase in resource use although economic evidence from the model for review question B1 strongly suggested that such treatments were cost effective when compared to non-hormonal moisturisers and lubricants.</p></div><div id="niceng23er3.s1.1.10.5"><h5>Other factors the committee took into account</h5><p>The committee discussed that the decision to use local vaginal oestrogens for the treatment of genitourinary symptoms, in those with a personal history of breast cancer, should be made together with the person and the healthcare professional. They agreed that the evidence needed to be considered together with each individual person’s risk of recurrence, and that this discussion should be a shared decision. Therefore, they agreed to cross refer to the <a href="https://www.nice.org.uk/guidance/ng197/chapter/Recommendations#putting-shared-decision-making-into-practice" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE guideline on shared decision making</a> and the <a href="https://www.nice.org.uk/guidance/ng101" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE guideline on early and locally advanced breast cancer</a>.</p></div></div><div id="niceng23er3.s1.1.11"><h4>Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.5.13 to 1.5.18 and research recommendations 5 on the impact of vaginal oestrogen on breast cancer recurrence in the NICE guideline.</p><p>The committee noted that there is 1 recommendation in the NICE guideline that is relevant to all women regardless of whether or not they have a history of breast cancer (recommendations 1.5.17 – on vaginal laser treatment) but this was underpinned by evidence and discussions in evidence review B1 – managing genitourinary symptoms (network meta-analysis).</p></div></div><div id="niceng23er3.s1.rl.r1"><h3>References – included studies</h3><ul class="simple-list"><div id="niceng23er3.s1.rl.r1.1"><h4>Effectiveness</h4><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="niceng23er3.s1.1.ref1"><p id="p-95">
|
|
<strong>Cold 2022</strong>
|
|
</p>Cold, Soren; Cold, Frederik; Jensen, Maj-Britt; Cronin-Fenton, Deirdre; Christiansen, Peer; Ejlertsen, Bent; Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.; Journal of the National Cancer Institute; 2022 [<a href="/pmc/articles/PMC9552278/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9552278</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35854422" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35854422</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng23er3.s1.1.ref2"><p id="p-96">
|
|
<strong>Dew 2003</strong>
|
|
</p>Dew, J E; Wren, B G; Eden, J A; A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer; Climacteric: the journal of the International Menopause Society; 2003; vol. 6 (no. 1); 45-
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12725664" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12725664</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng23er3.s1.1.ref3"><p id="p-97">
|
|
<strong>Le Ray 2012</strong>
|
|
</p>Le Ray, Isabelle; Dell’Aniello, Sophie; Bonnetain, Franck; Azoulay, Laurent; Suissa, Samy; Local estrogen therapy and risk of breast cancer recurrence among; Breast Cancer Res. Treat.; 2012; vol. 135 (no. 2); 603–609
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22903687" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22903687</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng23er3.s1.1.ref4"><p id="p-98">
|
|
<strong>O’Meara 2001</strong>
|
|
</p>O’Meara
|
|
ES, Rossing
|
|
MA, Daling
|
|
JR
|
|
et al. (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. Journal of the National Cancer Institute
|
|
93(10): 754–762
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11353785" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11353785</span></a>]</div></p></li></ul></div><div id="niceng23er3.s1.rl.r1.2"><h4>Economic</h4><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="niceng23er3.s1.1.ref5"><p id="p-99">
|
|
<strong>Dymond 2021</strong>
|
|
</p>Dymond, A; Holmes, H; McMaster, J; Craig, J; Davies, H; Mealing, S. and Perard, R; 2021. Economic Evaluation of Senshio®(Ospemifene) for the Treatment of Vulvovaginal Atrophy in Scotland. Applied Health Economics and Health Policy, 19, pp.123–132.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32390072" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32390072</span></a>]</div></p></li></ul></div></ul></div></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng23er3.appa"><h3>Appendix A. Review protocols</h3><p id="niceng23er3.appa.et1"><a href="/books/NBK609658/bin/niceng23er3-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Review protocol for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</a><span class="small"> (PDF, 191K)</span></p></div><div id="niceng23er3.appb"><h3>Appendix B. Literature search strategies</h3><p id="niceng23er3.appb.et1"><a href="/books/NBK609658/bin/niceng23er3-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Literature search strategies for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</a><span class="small"> (PDF, 265K)</span></p></div><div id="niceng23er3.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng23er3.appc.et1"><a href="/books/NBK609658/bin/niceng23er3-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Study selection for: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</a><span class="small"> (PDF, 178K)</span></p></div><div id="niceng23er3.appd"><h3>Appendix D. Evidence tables</h3><p id="niceng23er3.appd.et1"><a href="/books/NBK609658/bin/niceng23er3-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Evidence tables for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</a><span class="small"> (PDF, 271K)</span></p></div><div id="niceng23er3.appe"><h3>Appendix E. Forest plots</h3><p id="niceng23er3.appe.et1"><a href="/books/NBK609658/bin/niceng23er3-appe-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Forest plots for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</a><span class="small"> (PDF, 120K)</span></p></div><div id="niceng23er3.appf"><h3>Appendix F. GRADE tables</h3><p id="niceng23er3.appf.et1"><a href="/books/NBK609658/bin/niceng23er3-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">GRADE tables for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</a><span class="small"> (PDF, 138K)</span></p></div><div id="niceng23er3.appg"><h3>Appendix G. Economic evidence study selection</h3><div id="niceng23er3.appg.s1"><h4>Study selection for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</h4><p>A single economic search was undertaken for all topics included in the scope of this guideline. See <a href="/books/NBK609658/bin/NG23-Menopause-supplement-2-health-economics.pdf">Supplement 2</a> for further information.</p></div></div><div id="niceng23er3.apph"><h3>Appendix H. Economic evidence tables</h3><div id="niceng23er3.apph.s1"><h4>Economic evidence tables for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</h4><p>No evidence was identified which was applicable to this review question.</p></div></div><div id="niceng23er3.appi"><h3>Appendix I. Economic model</h3><div id="niceng23er3.appi.s1"><h4>Economic model for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</h4><p>No economic analysis was conducted for this review question.</p></div></div><div id="niceng23er3.appj"><h3>Appendix J. Excluded studies</h3><div id="niceng23er3.appj.s1"><h4>Excluded studies for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</h4><div id="niceng23er3.appj.s1.1"><h5>Excluded effectiveness studies</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng23er3appjtab1"><a href="/books/NBK609658/table/niceng23er3.appj.tab1/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img" rid-ob="figobniceng23er3appjtab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng23er3.appj.tab1"><a href="/books/NBK609658/table/niceng23er3.appj.tab1/?report=objectonly" target="object" rid-ob="figobniceng23er3appjtab1">Table 6</a></h4><p class="float-caption no_bottom_margin">Excluded studies and reasons for their exclusion. </p></div></div></div><div id="niceng23er3.appj.s1.2"><h5>Excluded economic studies</h5><p>No economic evidence was identified for this review. See <a href="/books/NBK609658/bin/NG23-Menopause-supplement-2-health-economics.pdf">Supplement 2</a> for further information.</p></div></div></div><div id="niceng23er3.appk"><h3>Appendix K. Research recommendations – full details</h3><p id="niceng23er3.appk.et1"><a href="/books/NBK609658/bin/niceng23er3-appk-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Research recommendations for review question: Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?</a><span class="small"> (PDF, 152K)</span></p></div></div></div><div class="fm-sec"><div><p>FINAL</p></div><div><p>Evidence reviews underpinning recommendations 1.5.13 to 1.5.18 and research recommendations 5 in the NICE guideline</p><p>These evidence reviews were developed by NICE</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2024.</div><div class="small"><span class="label">Bookshelf ID: NBK609658</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39631005" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">39631005</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng23er3tab1"><div id="niceng23er3.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">Summary of the protocol (PICO table)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609658/table/niceng23er3.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng23er3.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng23er3.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng23er3.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Women with genitourinary symptoms associated with the menopause transition and a personal history of breast cancer or otherwise at high risk of developing breast cancer (for example <i>BRCA1/2</i> carriers)</td></tr><tr><th id="hd_b_niceng23er3.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><td headers="hd_b_niceng23er3.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Local oestrogen (different preparations will be considered)</div></li><li class="half_rhythm"><div>Ospemifene</div></li><li class="half_rhythm"><div>Prasterone</div></li><li class="half_rhythm"><div>Transvaginal laser therapy</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng23er3.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison</th><td headers="hd_b_niceng23er3.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Placebo (this may include non-hormonal treatment, including moisturisers and lubricants)</div></li><li class="half_rhythm"><div>Sham treatment</div></li><li class="half_rhythm"><div>No treatment</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng23er3.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome</th><td headers="hd_b_niceng23er3.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical</b>
|
|
<ul><li class="half_rhythm"><div>Incidence (or recurrence) of breast cancer</div></li></ul>
|
|
<b>Important</b>
|
|
<ul><li class="half_rhythm"><div>Incidence of ovarian cancer</div></li><li class="half_rhythm"><div>Incidence of endometrial cancer</div></li></ul></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng23er3tab2"><div id="niceng23er3.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of included studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609658/table/niceng23er3.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng23er3.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng23er3.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng23er3.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><th id="hd_h_niceng23er3.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng23er3.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison</th><th id="hd_h_niceng23er3.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th></tr></thead><tbody><tr><td headers="hd_h_niceng23er3.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng23er3.s1.1.ref1" rid="niceng23er3.s1.1.ref1">Cold 2022</a>
|
|
</p>
|
|
<p>Prospective cohort study</p>
|
|
<p>Denmark</p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>N=8328 women with breast cancer</p>
|
|
<p>Age <65 years - number (%):</p>
|
|
<p>Vaginal oestrogen therapy (VET): 1327 (68%)</p>
|
|
<p>Never-users: 4047 (64%)</p>
|
|
<p>Age ≥65 years - number (%):</p>
|
|
<p>VET: 630 (32%)</p>
|
|
<p>Never-users: 2297 (36%)</p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Breast cancer recurrence</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng23er3.s1.1.ref2" rid="niceng23er3.s1.1.ref2">Dew 2003</a>
|
|
</p>
|
|
<p>Retrospective cohort study</p>
|
|
<p>Australia</p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>N=1472 women with breast cancer</p>
|
|
<p>Age, mean (range): only reported by group rather than overall:
|
|
<ul><li class="half_rhythm"><div>Vaginal oestrogen users: 53.8 (22-83)</div></li><li class="half_rhythm"><div>All other participants: 55.6 (21-96)</div></li></ul></p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Breast cancer recurrence</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng23er3.s1.1.ref3" rid="niceng23er3.s1.1.ref3">Le Ray 2012</a>
|
|
</p>
|
|
<p>Retrospective cohort study</p>
|
|
<p>UK</p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>N=10933 women with breast cancer</p>
|
|
<p>Used tamoxifen or aromatase inhibitors</p>
|
|
<p>Age, mean (SD) years: 63.1 (13.7)</p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Breast cancer recurrence</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng23er3.s1.1.ref4" rid="niceng23er3.s1.1.ref4">O’ Meara 2001</a>
|
|
</p>
|
|
<p>Retrospective cohort study</p>
|
|
<p>United States</p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>N=869 women with breast cancer</p>
|
|
<p>Age, mean (SD) years: NR (overall or by group)</p>
|
|
</td><td headers="hd_h_niceng23er3.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No vaginal oestrogen</td><td headers="hd_h_niceng23er3.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Breast cancer recurrence</div></li></ul>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">NR: not reported; SD: standard deviation</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng23er3appjtab1"><div id="niceng23er3.appj.tab1" class="table"><h3><span class="label">Table 6</span><span class="title">Excluded studies and reasons for their exclusion</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609658/table/niceng23er3.appj.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng23er3.appj.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Code [Reason]</th></tr></thead><tbody><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Areas, Fernanda, Valadares, Ana L R, Conde, Delio Marques
|
|
et al. (2019) The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. Menopause (New York, N.Y.)
|
|
26(9): 1052–1058
|
|
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31453969" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31453969</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Barton, Debra L, Shuster, Lynne T, Dockter, Travis
|
|
et al. (2018) Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
|
|
26(4): 1335–1343
|
|
[<a href="/pmc/articles/PMC5823730/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5823730</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29164377" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29164377</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Barton, Debra L, Sloan, Jeff A, Shuster, Lynne T
|
|
et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
|
|
26(2): 643–650
|
|
[<a href="/pmc/articles/PMC5754227/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5754227</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28921241" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28921241</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Becorpi, Angelamaria, Campisciano, Giuseppina, Zanotta, Nunzia
|
|
et al. (2018) Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers in medical science
|
|
33(5): 1047–1054
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29492713" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29492713</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Biglia, Nicoletta, Peano, Elisa, Sgandurra, Paola
|
|
et al. (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
|
|
26(6): 404–12
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20196634" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20196634</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bruyniks, N, Biglia, N, Palacios, S
|
|
et al. (2017) Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric : the journal of the International Menopause Society
|
|
20(3): 195–204
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28267367" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28267367</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>Not breast cancer or high risk population</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Chambers, Laura M, Herrmann, Alyssa, Michener, Chad M
|
|
et al. (2020) Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
|
|
30(4): 515–524
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32075898" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32075898</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p><i>Women had a previous history of cervical, endometrial or ovarian cancer - not breast cancer. Less than 33% (18%) had a history of ovarian cancer</i>.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Crandall, Carolyn J; Diamant, Allison; Santoro, Nanette (2020) Safety of vaginal estrogens: a systematic review. Menopause (New York, N.Y.)
|
|
27(3): 339–360
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31913230" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31913230</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>Systematic review - no included studies in women with/at risk of breast cancer</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Crandall, Carolyn J, Hovey, Kathleen M, Andrews, Christopher A
|
|
et al. (2018) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause (New York, N.Y.)
|
|
25(1): 11–20
|
|
[<a href="/pmc/articles/PMC5734988/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5734988</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28816933" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28816933</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>Not women with breast cancer or at high risk</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Di Donato, Violante, Schiavi, Michele Carlo, Iacobelli, Valentina
|
|
et al. (2019) Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety. Maturitas
|
|
121: 93–100
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30509754" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30509754</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>Not breast cancer or high-risk population</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gambacciani, Marco and Levancini, Marco (2017) Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause (New York, N.Y.)
|
|
24(3): 316–319
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28231079" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28231079</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gardner, Alyssa N and Aschkenazi, Sarit O (2021) The short-term efficacy and safety of fractional CO2 laser therapy for vulvovaginal symptoms in menopause, breast cancer, and lichen sclerosus. Menopause (New York, N.Y.)
|
|
28(5): 511–516
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33399322" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33399322</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gittens, Paul and Mullen, Gregory (2019) The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
|
|
21(3): 127–131
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29883233" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29883233</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Harris, Benjamin S, Bishop, Katherine C, Kuller, Jeffrey A
|
|
et al. (2020) Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause (New York, N.Y.)
|
|
27(2): 243–248
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31738735" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31738735</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design</p>
|
|
<p>
|
|
<i>Systematic review checked for relevant studies</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hirschberg, Angelica Linden, Sanchez-Rovira, Pedro, Presa-Lorite, Jesus
|
|
et al. (2020) Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause (New York, N.Y.)
|
|
27(5): 526–534
|
|
[<a href="/pmc/articles/PMC7188038/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7188038</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32049923" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32049923</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hocke, C, Diaz, M, Bernard, V
|
|
et al. (2021) [Genitourinary Menopause Syndrome. CNGOF and GEMVi clinical practice guidelines]. Gynecologie, obstetrique, fertilite & senologie [<a href="https://pubmed.ncbi.nlm.nih.gov/33757926" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33757926</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Language</p>
|
|
<p>
|
|
<i>Not English language</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Jha, Swati; Wyld, Lynda; Krishnaswamy, Priyanka H (2019) The Impact of Vaginal Laser Treatment for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review and Meta-analysis. Clinical breast cancer
|
|
19(4): e556–e562
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31227415" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31227415</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Knight, Charity; Logan, Vera; Fenlon, Deborah (2019) A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. Ecancermedicalscience
|
|
13: 988
|
|
[<a href="/pmc/articles/PMC6974376/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6974376</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32010212" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32010212</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lethaby, Anne; Ayeleke, Reuben Olugbenga; Roberts, Helen (2016) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews
|
|
8(8): cd001500 [<a href="/pmc/articles/PMC7076628/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7076628</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27577677" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27577677</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>Not breast cancer or high risk</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Li, Bohan, Duan, Hua, Chang, Yanan
|
|
et al. (2021) Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. Pharmacological research
|
|
164: 105360
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33307219" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33307219</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lyytinen, H.; Pukkala, E.; Ylikorkala, O. (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstetrics and Gynecology
|
|
108(6): 1354–1360
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17138766" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17138766</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>Not women with/ at risk of breast cancer</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mension, Eduard; Alonso, Inmaculada; Castelo-Branco, Camil (2021) Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors - Systematic Review. Maturitas
|
|
143: 47–58
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33308636" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33308636</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design</p>
|
|
<p>
|
|
<i>Systematic review checked for relevant studies</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Moegele, M, Buchholz, S, Seitz, S
|
|
et al. (2012) Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Archives of gynecology and obstetrics
|
|
285(5): 1397–402
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22212649" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22212649</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design</p>
|
|
<p>
|
|
<i>Systematic review checked for relevant studies</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mothes, A R; Runnebaum, M; Runnebaum, I B (2018) Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. Journal of cancer research and clinical oncology
|
|
144(5): 955–960
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29487993" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29487993</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pagano, Tiziana, De Rosa, Pasquale, Vallone, Roberta
|
|
et al. (2018) Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause (New York, N.Y.)
|
|
25(6): 657–662
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29286986" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29286986</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pavlovic, R T, Jankovic, S M, Milovanovic, J R
|
|
et al. (2019) The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis. Clinical breast cancer
|
|
19(6): e731–e740
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31522958" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31522958</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pearson, Antonia, Booker, Andrew, Tio, Martin
|
|
et al. (2019) Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. Breast cancer research and treatment
|
|
178(1): 135–140
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31377895" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31377895</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pieralli, Annalisa, Fallani, Maria Grazia, Becorpi, Angelamaria
|
|
et al. (2016) Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Archives of gynecology and obstetrics
|
|
294(4): 841–6
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27170261" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27170261</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Quick, Allison M, Hundley, Andrew, Evans, Cynthia
|
|
et al. (2022) Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors. Journal of clinical medicine
|
|
11(3) [<a href="/pmc/articles/PMC8836519/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8836519</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35160226" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35160226</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Saeaib, Nungrutai, Peeyananjarassri, Krantarat, Liabsuetrakul, Tippawan
|
|
et al. (2020) Hormone replacement therapy after surgery for epithelial ovarian cancer. The Cochrane database of systematic reviews
|
|
1: cd012559
|
|
[<a href="/pmc/articles/PMC7027384/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7027384</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31989588" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31989588</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Intervention</p>
|
|
<p>
|
|
<i>No relevant interventions</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sanchez-Rovira, Pedro, Hirschberg, Angelica Linden, Gil-Gil, Miguel
|
|
et al. (2020) A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. The oncologist
|
|
25(12): e1846–1854
|
|
[<a href="/pmc/articles/PMC8108054/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8108054</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32459035" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32459035</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Simon, James A, Altomare, Corrado, Cort, Susannah
|
|
et al. (2018) Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials. Journal of women’s health (2002)
|
|
27(1): 14–23 [<a href="/pmc/articles/PMC5771532/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5771532</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29064335" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29064335</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>Not breast cancer or high risk</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Tranoulis, Anastasios; Georgiou, Dimitra; Michala, Lina (2019) Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?. International urogynecology journal
|
|
30(11): 1879–1886
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31321465" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31321465</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wills, S;Ravipati, A;Venuturumilli, P.
|
|
et al. (2012) Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. Journal of Oncology Practice
|
|
8(3): 144–149
|
|
[<a href="/pmc/articles/PMC3396801/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3396801</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22942807" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22942807</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Outcome</p>
|
|
<p>
|
|
<i>Reported outcomes do not match the review protocol</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Zuo, Stephanie Wang; Wu, Harold; Shen, Wen (2018) Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors. Menopause (New York, N.Y.)
|
|
25(7): 828–836
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29533365" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29533365</span></a>]
|
|
</td><td headers="hd_h_niceng23er3.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Population</p>
|
|
<p>
|
|
<i>The case series excluded women with history of breast cancer</i>
|
|
</p>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|